Double blind cross-over study of a new appetite suppressant AN 448.
The effects of a new appetite suppressant, AN 448, and a placebo have been compared in 30 obese individuals using a fully randomized double-blind cross-over design. 1 mg of AN 448 t.i.d. produced a significant degree of appetite suppression and a mean weight loss of more than 4 kg per individual over a 6 week period. Side effects were few and no haematological, renal or hepatic damage was observed.
D001066:Appetite / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D008297:Male; D008454:Mazindol / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D009765:Obesity / Q000188:drug therapy*; D010919:Placebos; D011674:Pulse / Q000187:drug effects
D007211:Indoles; D010919:Placebos; D008454:Mazindol